Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 3/20 | 0.44 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | PDE5A | O76074 | 15/20 | 0.41 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7184738 | 1.00 | PDE7A (0.44) | PDE7APDE7BDRD4PDE5APDE2A | |
| SCHEMBL7185263 | 0.92 | PDE5A (0.47) | PDE7APDE7BDRD4PDE5APDE2A | |
| SCHEMBL7178544 | 0.92 | PDE5A (0.47) | PDE7APDE7BDRD4PDE5APDE2A | |
| SCHEMBL7178553 | 0.92 | PDE5A (0.47) | PDE7APDE7BDRD4PDE5APDE2A | |
| SCHEMBL7183896 | 0.92 | PDE7A (0.45) | PDE7APDE7BDRD4PDE5APDE2A | |
| SCHEMBL7192181 | 0.91 | PDE7A (0.45) | PDE7APDE7BDRD4PDE5APDE2A | |
| SCHEMBL7182981 | 0.91 | PDE7A (0.45) | PDE7APDE7BDRD4PDE5APDE2A | |
| SCHEMBL7183853 | 0.90 | PDE7A (0.44) | PDE7APDE7BDRD4PDE5APDE2A | |
| SCHEMBL7178238 | 0.90 | PDE1A (0.46) | PDE7APDE7BDRD4PDE5APDE2A | |
| SCHEMBL7191388 | 0.89 | PDE7A (0.47) | PDE7APDE7BDRD4PDE5APDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6582351-B1 | Benzimidazole heterocyclic compounds having pharmacological activities, and their use as a medicament for treatment or prevention of diseases mediated by cGMP-PDE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-24 | — | — | US | disclosed |